Daptomycin CAS 103060-53-3 Puritas ≥95.0% API Factory High Purity
Manufacturer cum High puritate et stabulo Quality
Nomen chemicum: Daptomycin
CAS: 103060-53-3
API High Quality, Commercial Production
Nomen chemicum | Daptomycin |
Synonyma | LY146032 |
CAS Number | 103060-53-3 |
CATTUS Number | RF-API10 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C72H101N17O26 |
M. Pondus | 1620.69 |
Liquescens punctum | 202.0~204.0℃ |
Solubilitas | Solube in Methanol |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Yellow vel pallide lutea pulveris |
Lepidium sativum HPLC | Retentionis tempus solutionis maioris cacuminis sample solutionis congruenti respondere debet vexillum relationis. |
Lepidium sativum IR | IR spectrum speciminis testi consentaneum esse debet cum IR spectro relationis vexillum. |
Solutio specie | Solutio claritatis perspicua vel non magis declarata quam relatio suspensionis II debet. |
Imprimis Rotatione Optica | +17.0° to +25.0° |
pH | 4.0 ad 5.0 |
Residere in Ignition | ≤1.0% |
Anhydro-Daptomycin | ≤2.5% |
β-Isomer | ≤0.50% |
Hydrolysis immunditia | ≤0.50% |
immunditia 1 | ≤0.75% |
Impurtiy 2 | ≤0.75% |
Impurtiy 3 | ≤0.75% |
Alia immunditia | ≤0.15% |
Totalis immunditias | ≤5.0% |
Metalla gravis | ≤30ppm |
Aqua | ≤5.0% |
Puritas | ≥95.0% (calculata in exaruit basis) |
Bacterial Endotoxins | <0.3EU/mg |
Residua Solvents n-Butanol | ≤5000ppm |
ResidualSolvents Isopropanol | ≤5000ppm |
RELICTUM Solvents Ethanol | ≤5000ppm |
Microbial Low TAMC | ≤100cfu/g* |
Microbial Low TYMC | ≤10cfu/g* |
E.Coil | Non Results |
Test Standard | Enterprise Standard |
Repono Conditions | Serva in strictis vasis et repone ante -25~-10℃. |
Consuetudinem | Active Pharmaceutical Ingredient (API) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Daptomycin (CAS: 103060-53-3) est genus antibioticorum cyclici lipopeptidis cum structura nova.Extrahitur e struthomyceis fermenti ius.Inventa est ab Eli Lilly Company in 1980s, et feliciter elaborata est in pharmaceutica Cubist 1997.Is non solum novam chemicam structuram habens, sed etiam modum agendi habet, qui ab antibiotico aliquo ante probato diversus est: cellulam amino acida per membranam cellam transportandam perturbando, ita claudendo paries cellae peptidoglycans biosynthesin et naturam mutans. membranam.Membranam cellularum bacterial munus multis aspectibus destruere potest et cito bacteria gram-positivam necant.Praeter munus effectum obtinendi in bacteria maxime amet gram-positiva pertinentes, potius Daptomycin vim habet potentem in modos solitarios tractandi qui signa resistendi methicillino, vancomycin et linezolid ostenderunt.Haec proprietas magnae significationis clinicae est aegris gravi infectione laborantibus.Mense Septembri 2003, Cibus et Administration US medicamentum primum probaverat Daptomycin (CAS: 103060-53-3) applicari posse ad curationem infectionum gravium cutis.Mense Martio 2006 probata est de morbis contagiosis curandis.Mense Ianuario MMVI, a Commissione Europaea approbata est de curatione quarundam infectionum cutis complicatarum et mollium textorum, quae per bacteria gram-positiva causantur.Die VI Septembris 2007, Cubista Pharmaceutica nuntiavit Unionem Europaeam sua antibacterial medicamento approbasse, Cubicinum ad curationem cordis endocarditis recti a Staphylococco aurei contagione et intricata cute et molli telae contagione relato morborum Staphylococcorum aurei relatam.